Ilyang Pharmaceutical Co.,Ltd (KRX:007570)
South Korea · Delayed Price · Currency is KRW 8,430.00
+50.00 (0.60%)
Aug 3, 2026, 3:30 PM KST
KRX:007570 Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 275,513 | 272,422 | 268,678 | 266,669 | 247,773 | 242,511 |
Revenue Growth | 1.31% | 1.39% | 0.75% | 7.63% | 2.17% | -29.37% |
Gross Profit Gross Profit Growth | 112,217 | 116,280 | 111,217 | 116,404 | 108,194 | 104,646 |
Operating Income Operating Income Growth | -5,790 | 4,963 | 9,622 | 16,379 | 14,249 | 15,188 |
Net Income Net Income Growth | 19,541 | 6,727 | 9,032 | -2,321 | 18,933 | 14,032 |
Earnings Per Share EPS Growth | 1116.30 | 374.81 | 490.00 | -131.00 | 1044.53 | 770.78 |
EPS Growth | 94.73% | -23.51% | - | - | 35.52% | 29.11% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 39,658 | 29,627 | 12,790 | 13,690 | 12,593 | 43,631 |
Total Debt Total Debt Growth | 112,646 | 126,794 | 107,681 | 72,650 | 74,103 | 98,503 |
Net Cash (Debt) Net Cash Growth | -72,988 | -97,168 | -94,891 | -58,960 | -61,511 | -54,872 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -4169.47 | -5414.14 | -5148.09 | -3272.13 | -3393.60 | -3014.10 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 43,508 | 12,041 | 5,615 | 14,619 | 5,883 | 51,429 |
Capital Expenditures CapEx Growth | -5,689 | -5,717 | -38,200 | -5,883 | -3,946 | -12,371 |
Free Cash Flow Free Cash Flow Growth | 37,819 | 6,323 | -32,585 | 8,736 | 1,938 | 39,057 |
Free Cash Flow Growth | - | - | - | 350.88% | -95.04% | -17.44% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 40.73% | 42.68% | 41.39% | 43.65% | 43.67% | 43.15% |
Operating Margin | -2.10% | 1.82% | 3.58% | 6.14% | 5.75% | 6.26% |
Pretax Margin | 10.10% | 4.87% | 4.06% | -0.67% | 9.62% | 9.10% |
Profit Margin | 7.09% | 2.47% | 3.36% | -0.87% | 7.64% | 5.79% |
FCF Margin | 13.73% | 2.32% | -12.13% | 3.28% | 0.78% | 16.11% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Dividend Per Share Dividend Per Share Growth | 155.000 | - | - | 150.000 |
Dividend Per Share Growth | 3.33% | - | - | - |
Dividend Yield | 1.85% | - | - | 0.98% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 7.55 | 34.77 | 22.76 | - | 18.49 | 36.39 |
Forward PE | - | 49.90 | 49.90 | 49.90 | 49.90 | 49.90 |
P/FCF Ratio | 4.00 | 36.99 | - | 32.19 | 180.62 | 13.07 |
PS Ratio | 0.55 | 0.86 | 0.77 | 1.06 | 1.41 | 2.11 |